uniQure (NASDAQ:QURE) Given New $31.00 Price Target at Chardan Capital

uniQure (NASDAQ:QURE) had its price target upped by investment analysts at Chardan Capital from $16.00 to $31.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price objective would indicate a potential upside of 77.95% from the company’s current price.

Other analysts have also issued research reports about the company. Leerink Partners reissued an “outperform” rating and set a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $11.00 to $35.00 in a research note on Monday. Stifel Nicolaus set a $14.00 price objective on shares of uniQure in a research note on Monday, March 2nd. TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, The Goldman Sachs Group cut their price target on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $41.33.

uniQure Stock Performance

NASDAQ QURE traded up $3.15 during midday trading on Monday, hitting $17.42. The company had a trading volume of 11,932,201 shares, compared to its average volume of 3,653,700. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -5.05 and a beta of 0.73. The firm has a fifty day simple moving average of $22.04 and a two-hundred day simple moving average of $29.63. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. Equities analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In other uniQure news, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 12,000 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the completion of the transaction, the chief financial officer owned 226,581 shares in the company, valued at $2,052,823.86. The trade was a 5.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 81,399 shares of company stock worth $1,527,645. 4.79% of the stock is currently owned by insiders.

Institutional Trading of uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP grew its holdings in uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 35,175 shares during the period. Teacher Retirement System of Texas bought a new stake in uniQure in the second quarter valued at about $151,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in uniQure in the second quarter valued at about $215,000. SG Americas Securities LLC acquired a new position in uniQure in the second quarter valued at about $1,321,000. Finally, Main Management ETF Advisors LLC boosted its holdings in uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after buying an additional 912 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Major analyst upgrades lift sentiment — Wells Fargo upgraded uniQure to “overweight” with a $60 price target and RBC raised its rating to “outperform” with a $35 target; both moves signal large upside expectations and likely contributed to buying interest. Wells Fargo Upgrade
• Positive Sentiment: Market rallied on regulatory staffing news — reports that FDA CBER official Vinay Prasad plans to exit in April triggered a sectorwide bounce and was cited as a proximate cause of uniQure’s intraday surge. This appears to have reduced near-term regulatory overhang in traders’ eyes. uniQure stock surges on FDA official departure
• Neutral Sentiment: Analysts flag upcoming clinical catalysts — coverage noting uniQure among biotechs with asymmetric upside ahead of binary drug-readout events may support speculative interest, but outcomes remain binary and high-risk. Analyst Interest Ahead of Catalysts
• Neutral Sentiment: Retail/celebrity portfolio coverage — stories noting large unrealized losses in a public investor’s portfolio draw attention but have limited direct impact on fundamentals. TipRanks coverage
• Negative Sentiment: Class-action lawsuits announced — Portnoy Law Firm and Rosen Law Firm have publicized securities class actions covering purchases between Sept. 24 and Oct. 31, 2025; potential legal exposure and related PR/settlement risk add downside pressure and uncertainty. Portnoy Law Firm class action
• Negative Sentiment: Ongoing FDA scrutiny and changing trial demands — coverage (Genetic Engineering & Biotechnology News, Yahoo Finance) highlights that FDA requests around the AMT-130 program have reshaped expectations; regulatory friction remains a material risk for timelines and approvals. Regulatory scrutiny coverage

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.